NCATS SBIR Phase II
Backs small businesses scaling proven translational findings into applied solutions and early market readiness.
The National Center for Advancing Translational Sciences (NCATS) administers SBIR Phase II grants (R44) to support expanded research, development, and early commercialization activities for small US businesses that have demonstrated feasibility in a Phase I award. NCATS's four priority topic areas — preclinical drug discovery and development, biomedical and health research informatics, clinical an…
Expanded R&D and commercialization for small businesses in preclinical drug discovery, biomedical informatics, clinical and dissemination research, and rare disease applications.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline
Guides for this application
All guides →SBIR/STTR Grants for Deeptech Startups
A practical guide to SBIR and STTR grants for deeptech startups, including agency fit, Phase I and II logic, eligibility, budgets, and review criteria.
DocumentsNIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
More from NCATS
All grants from this funder →Oligonucleotide Toxicity (OligoTox) Open Data Challenge
🇺🇸NCATS · United States
Pays cash prizes for public datasets that help predict oligonucleotide drug toxicity in human cells.
NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NCATS STTR Phase II
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to continue and expand translational R&D begun in STTR Phase I toward a commercial product.
NCATS SBIR Phase I
🇺🇸NCATS · United States
Supports small businesses testing translational science tools and technologies through early feasibility and commercialization groundwork.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.
Similar grants
Browse the directory →
NSF SBIR Phase II
🇺🇸NSF · United States
Funds United States deep-tech startups extending proven early projects into substantial technology development.
NIH SBIR Phase II
🇺🇸NIH SEED · United States
Supports United States biomedical small businesses advancing successful feasibility work into scale-up development.
NEI SBIR Phase II — R&D
🇺🇸NEI · United States
Supports United States. small businesses scaling vision concepts into full development pathways.
NIH SBIR Phase II (Omnibus)
🇺🇸NIH · United States
Funds United States small businesses advancing validated biomedical innovations through substantial full development execution.
NSF STTR Phase II
🇺🇸NSF · United States
Funds United States deep-tech projects that continue with nonprofit research partners after successful initial feasibility work.
NIH SBIR Direct-to-Phase II (Omnibus)
🇺🇸NIH · United States
Funds United States small businesses moving directly into major development when early biomedical feasibility is already established.